The understanding and treatment of Pulmonary Hypertension is a rapidly growing field and yet there are still many unknowns
At Sydney Pulmonary Hypertension Specialists, we are actively involved in local and international research in this area to further develop our knowledge about this complicated and severe disease.
Pulmonary Hypertension Current Research
Pulmonary arterial hypertension (PAH) can be a progressive and severely limiting disease without treatment. The last two decades have seen an enormous improvement in the understanding of the pathological process of PAH and the development of new treatments through research and clinical trials but our knowledge of the best and most effective treatments is still limited.
We are members of the Pulmonary Hypertension Society of Australia and New Zealand and contribute data to their large patient database. This enables a greater understanding of the disease burden, progression and natural history within Australia and New Zealand. This information can be used to track our own patients and outcomes compared to National standards. It also helps in campaigning for greater funding and treatment access from the Australian government.
Combination therapies have been shown to be more effective than single therapies, but the best combination is still unknown. Newer treatments and modes of delivery are being developed every year.
The Sydney Pulmonary Hypertension Specialists are actively involved in clinical research in the area of pulmonary hypertension. This not only enables us to advance knowledge in this field but also allows us to access therapies not currently available to patients in Australia.
As such, you may be invited to consider participating in one these research trials and PHSANZ database (deidentified information). The PHSANZ database is an Opt-Out study, which means your deidentified information will automatically be retained unless you ask to opt out. Participation in trials is free of charge and your travel costs will be reimbursed. You are under no obligation to accept, and your treatment will not be affected in any way if you wish to decline.
Currently we are running the following trials. Please let us know if you would be interested in participating.
Australia and New Zealand database of all PHT patients, treatment and outcomes
A Phase 2/3 Study of the Efficacy and Safety of an Inhaled sGC Stimulator in Participants with Pulmonary Arterial Hypertension.
Enrollment commenced 2022
ADVANCE OUTCOMES (APD811-301)
A Study Evaluating the Efficacy and Safety of Ralinepag To Improve Treatment Outcomes in PAH Patients already on standard therapy.
Enrolment commencing 2019
ADVANCE CPET (APD811-302)
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Ralinepag to Evaluate Safety and Effects on Exercise Capacity Assessed by Cardiopulmonary Exercise Testing in Subjects with World Health Organization Group 1 Pulmonary Hypertension Who Recently Initiated Therapy
ADVANCE EXTENSION (APD811-303)
A Study Evaluating the Long-term Efficacy and Safety of Ralinepag in Subjects with PAH via an Open-label Extension (ADVANCE-Extension)
A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Clinical Worsening Study of UT-15C in Subjects with Pulmonary Arterial Hypertension Receiving Background Oral Monotherapy
Enrolment closed December 2017
An Open-Label Extension Study of UT-15C in Subjects with Pulmonary Arterial Hypertension - A Long-Term Follow-Up to Protocol TDE-PH-310
Enrolment commenced February 2016
These international studies compared oral treprostinil versus placebo three times a day for patients who were already on single background therapy. Thsi was a positive trial.
Inhaled nitric oxide/inopulse® delivery device for use in long-term symptomatic subjects with pulmonary hypertension and in subjects with pulmonary hypertension associated with chronic obstructive pulmonary disease (COPD)
Commenced Dec 2016. Ceased 2019
This international trial was for patients with PAH having home oxygen. It was comparing the addition of placebo to inhaled ambulatory nitric oxide for a minimum of 12 hours per day. It was ceased due to futility.
Cardiac 4D flow dynamics on cardiac MRI versus right heart catheterisation
This is a study of looking at four dimensional blood flow dynamics within the pulmonary artery in normal and pulmonary hypertensive patients using cardiac MRI. A voluntary component of this study will be comparing right heart pressures on right heart catheterisation with the flow dynamics on cardiac MRI. This is a multi institutional study within NSW.
Respiratory muscle training to improve exercise capacity and quality of life in people with pulmonary arterial hypertension
This study is investigating the effects of Respiratory Muscle Training on heart function, exercise capacity and quality of life in people with pulmonary arterial hypertension (PAH). This is a multi institutional study within NSW which is being led by RPA hospital.
Pulmonary Hypertension Society of Australia and New Zealand
The Thoracic Society of Australia and New Zealand (ANZCOTR)
The International Society for Heart & Lung Transplantation (ISHLT)
Lung Foundation Australia
St Vincents Hospital
Pulmonary Vascular Research Institute (PVRI)
Pulmonary Hypertension Association Australia (PHAA)